Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Major histocompatibility complex (MHC) class II genes are expressed constitutively in only a few cell types, but they can be induced in the majority of them, in particular by interferon-gamma (IFN-gamma). The MHC class II transactivator gene CIITA is defective in a form of primary MHC class II deficiency. Here it is shown that CIITA expression is controlled and induced by IFN-gamma. A functional CIITA gene is necessary for class II induction, and transfection of CIITA is sufficient to activate expression of MHC class II genes in class II-negative cells in the absence of IFN-gamma. CIITA is therefore a general regulator of both inducible and constitutive MHC class II expression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The expression of PD-L1 and MHC II, which may cause exhaustion by binding to T-cell programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3), respectively, is regulated by tumor interferon (IFN) signaling.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [27]
Citations
Cites
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
Gorman, C. M., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,830
Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor
Schindler, C., Shuai, K., Prezioso, V. R., & Darnell, J. E. (1992) · Science · doi:10.1126/science.1496401 · Cited by 899
Steimle, V (1993) · Cell · doi:10.1016/0092-8674(93)90685-j · Cited by 864
A Single Phosphotyrosine Residue of Stat91 Required for Gene Activation by Interferon-γ
Shuai, K., Stark, G. R., Kerr, L. M., & Darnell, J. E. (1993) · Science · doi:10.1126/science.7690989 · Cited by 802
Activation of Transcription by IFN-γ: Tyrosine Phosphorylation of a 91-kD DNA Binding Protein
Shuai, K., Schindler, C., Prezioso, V. R., & Darnell, J. E. (1992) · Science · doi:10.1126/science.1281555 · Cited by 775
Collins, T., Korman, A. J., Wake, C. T., Boss, J. M., Kappes, D. J., Fiers, W., Ault, K. A., Gimbrone, M. A., Strominger, J. L., & Pober, J. S. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.15.4917 · Cited by 585
Sequences And Factors: A Guide To Mhc Class-Ii Transcription
Glimcher, L. (1992) · Annual Review of Immunology · doi:10.1146/annurev.immunol.10.1.13 · Cited by 534
Benoist, C., & Mathis, D. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.003341 · Cited by 457
Müller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J. E., Stark, G. R., & Kerr, I. M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06106.x · Cited by 411
Detection of a novel human class II HLA antigen
Watson, A. J., DeMars, R., Trowbridge, I. S., & Bach, F. H. (1983) · Nature · doi:10.1038/304358a0 · Cited by 376
Cited by
Items 201–300 of 899
Deffrennes, V., Vedrenne, J., Stolzenberg, M., Piskurich, J. F., Barbieri, G., Ting, J. P. ‐., Charron, D. J., & Alcaïde‐Loridan, C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.98 · Cited by 82
“In addition, CIITA confers the tissue-specific expression of MHC class II molecules, with a constitutive expression in B lymphocytes (28) and dendritic cells, and an IFNg-responsive transcription in othercell lines (30).”
BackgroundSchnappinger, D., Schoolnik, G. K., & Ehrt, S. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2005.10.027 · Cited by 78
Chan, L. L. Y., Cheung, B. K. W., Li, J., & Lau, A. S. Y. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1009659 · Cited by 84
Wright, K. L., Chin, K.-C., Linhoff, M. W., Skinner, C., Brown, J. A., Boss, J. M., Stark, G. R., & Ting, J. P. ‐. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6267 · Cited by 68
van den Elsen, P. J., van der Stoep, N., Viëtor, H. E., Wilson, L., van Zutphen, M., & Gobin, S. J. P. (2000) · Human Immunology · doi:10.1016/s0198-8859(00)00159-2 · Cited by 72
Molecular defects in the bare lymphocyte syndrome and regulation of MHC class II genes
Reith, W., Steimle, V., & Mach, B. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80048-4 · Cited by 72
Wang, B., Reville, P. K., Yassouf, M. Y., Jelloul, F. Z., Ly, C. P., Desai, P. N., Wang, Z., Borges, P., Veletić, I., Dasdemir, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45916-6 · Cited by 86
Li, Y.-R., Zhou, Y., Yu, J., Zhu, Y., Lee, D., Zhu, E., Li, Z., Kim, Y. J., Zhou, K., Fang, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.005 · Cited by 76
“24 In this study, we have harnessed a synergistic approach that integrates iNKT TCR gene engineering and CRISPR-Cas9 gene editing on HSCs, as well as a feeder-free HSC differentiation culture.”
Lin, R., TARR, P. E., & Jones, T. C. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.6.1439 · Cited by 71
Clausen, B. E., Waldburger, J., Schwenk, F., Barras, E., Mach, B., Rajewsky, K., Förster, I., & Reith, W. (1998) · Immunity · doi:10.1016/s1074-7613(00)80467-7 · Cited by 72
Haimon, Z., Frumer, G. R., Kim, J., Trzebanski, S., Haffner‐Krausz, R., Ben‐Dor, S., Porat, Z., Muschaweckh, A., Chappell‐Maor, L., Boura‐Halfon, S., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01360-6 · Cited by 76
Villard, J., Masternak, K., Lisowska‐Grospierre, B., Fischer, A., & Reith, W. (2001) · Medicine · doi:10.1097/00005792-200111000-00006 · Cited by 69
Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases
Chow, S. C. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0038-5 · Cited by 73
“The mechanism now identified involves statins blocking the IFN-γ-inducible expression of the MHC class II transactivator (CIITA) promoter pIV, which is the master regulator of MHC class II expression (Kwak et al. 2001; Steimle et al. 1994).”
BackgroundCressman, D. E., O’Connor, W. J., Greer, S. F., Zhu, X., & Ting, J. P. ‐. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.3626 · Cited by 77
Bontron, S., Ucla, C., Mach, B., & Steimle, V. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4249 · Cited by 69
Zhu, X., & Ting, J. P. ‐. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.7078-7088.2001 · Cited by 69
“335 to generate FlagCIITA(1-335) using the QuickChange mutagenesis protocol”
BackgroundMethodInfluentialEmerging roles of astrocytes as immune effectors in the central nervous system
Fisher, T. M., & Liddelow, S. A. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.08.008 · Cited by 78
Ghosh, N., Győry, I., Wright, G. M., Wood, J., & Wright, K. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100862200 · Cited by 68
Open pulled straw (OPS) vitrification: A new way to reduce cryoinjuries of bovine ova and embryos
Vajta, G., Holm, P., Kuwayama, M., Booth, P. J., Jacobsen, H., Greve, T., & Callesen, H. (1998) · Molecular Reproduction and Development · doi:10.1002/(sici)1098-2795(199809)51:1<53::aid-mrd6>3.0.co;2-v · Cited by 1,048
Mutation of RFXAP, a Regulator of MHC Class II Genes, in Primary MHC Class II Deficiency
Villard, J., Lisowska‐Grospierre, B., van den Elsen, P. J., Fischer, A., Reith, W., & Mach, B. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371104 · Cited by 68
PML promotes MHC class II gene expression by stabilizing the class II transactivator
Ulbricht, T., Alzrigat, M., Horch, A., Reuter, N., von Mikecz, A., Steimle, V., Schmitt, E., Krämer, O. H., Stamminger, T., & Hemmerich, P. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201112015 · Cited by 67
“CIITA expression is induced by IFN- through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway, and expression of exogenous CIITA is sufficient to induce MHC class II expression in many different cell types (Steimle et al., 1994).”
New Insights into Graft-Versus-Host Disease and Graft Rejection
Perkey, E., & Maillard, I. P. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043720 · Cited by 75
“CIITA expression itself is controlled by several promoters that are differentially active in various cellular subsets.”
BackgroundInfluentialFlaumenhaft, R. C., Furie, B., & Furie, B. C. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199904)179:1<11::aid-jcp2>3.0.co;2-7 · Cited by 18
Sendide, K., Deghmane, A., Reyrat, J., Talal, A., & Hmama, Z. (2004) · Infection and Immunity · doi:10.1128/iai.72.7.4200-4209.2004 · Cited by 74
“IFN- regulates the expression of class II genes primarily at the level of transcription, and this requires induction of the class II transactivator (CIITA) (40); expression of the CIITA gene itself is dependent on STAT1 signaling (6, 7, 43).”
BackgroundItoh-Lindstrom, Y., Piskurich, J. F., Felix, N. J., Wang, Y., Brickey, W. J., Platt, J. L., Koller, B. H., & Ting, J. P. ‐. (1999) · PubMed · Cited by 66
van der Stoep, N., Biesta, P. J., Quinten, E., & van den Elsen, P. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1623 · Cited by 66
Saraav, I., Singh, S., & Sharma, S. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.52 · Cited by 80
Aquino‐López, A., Senyukov, V., Vlasic, Z., Kleinerman, E. S., & Lee, D. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00391 · Cited by 75
Haabeth, O. A. W., Fauskanger, M., Manzke, M., Lundin, K. U., Corthay, A., Bogen, B., & Tveita, A. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2426 · Cited by 76
Tosi, G., Jabrane‐Ferrat, N., & Peterlin, B. M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf557 · Cited by 65
Ye, K., Li, F., Wang, R., Cen, T., Liu, S., Zhao, Z., Li, R., Xu, L., Zhang, G.-M., Xu, Z.-Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.010 · Cited by 67
“Although MHC II is usually not expressed by solid tumors, its expression in tumor cells can be induced by IFN-g , 34 forming a positive feedback loop between T cell activation and MHC II induction in tumor cells.”
Collagen α1(I) Gene (COL1A1) Is Repressed by RFX Family
Sengupta, P. K., Xu, Y., Wang, L., Widom, R. L., & Smith, B. D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413191200 · Cited by 72
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
Donor dependent, interferon-γinduced HLA-DR expression on human neutrophilsin vivo
Reinisch, W., Lichtenberger, C., Steger, G. G., Tillinger, W., Scheiner, O., Gangl, A., Maurer, D., & Willheim, M. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02245.x · Cited by 67
Cytotoxic Proteins and Therapeutic Targets in Severe Cutaneous Adverse Reactions
Su, S., & Chung, W. (2014) · Toxins · doi:10.3390/toxins6010194 · Cited by 70
“More strikingly, IFN-γ is known to promote antigen presentation and thus stimulate the cell-mediated immunity by upregulation of MHC molecules [85,91,92], further supporting a pathogenic role in SJS/TEN.”
BackgroundSmith, M. A., Wright, G., Wu, J., Tailor, P., Ozato, K., Chen, X., Wei, S., Piskurich, J. F., Ting, J. P.-Y., & Wright, K. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.165431 · Cited by 61
Lang, C., Algner, M., Beinert, N., Groß, U., & Lüder, C. G. K. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.02.031 · Cited by 63
The RFX Family Interacts at the Collagen (COL1A2) Start Site and Represses Transcription
Sengupta, P. K., Fargo, J., & Smith, B. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111712200 · Cited by 63
Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition
Sottile, R., Federico, G., Garofalo, C., Tallerico, R., Faniello, M. C., Quaresima, B., Cristiani, C. M., Sanzo, M. D., Cuda, G., Ventura, V., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00224 · Cited by 67
“The INF-γ production increases MHC class II (43), PD-L1, and CD86 on APCs (42).”
BackgroundThe role of the MDM2/p53 axis in antitumor immune responses
Brummer, T., & Zeiser, R. (2024) · Blood · doi:10.1182/blood.2023020731 · Cited by 60
Xu, D., Trajkovic, V., Hunter, D., Leung, B. P., Schulz, K., Gracie, J. A., McInnes, I. B., & Liew, F. Y. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200011)30:11<3147::aid-immu3147>3.0.co;2-j · Cited by 153
Yao, Y., Xu, Q., Kwon, M.-J., Matta, R., Liu, Y., Hong, S.-C., & Chang, C.-H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.70 · Cited by 62
Krawczyk, M., Peyraud, N., Rybtsova, N., Masternak, K., Bücher, P., Barras, E., & Reith, W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6200 · Cited by 62
“This is mediated by the activation of CIITA expression and its recruitment to the enhanceosome assembled on MHC-II promoters (23, 40, 42).”
BackgroundLi, G., Harton, J. A., Zhu, X., & Ting, J. P. ‐. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4626-4635.2001 · Cited by 63
“The constitutive and inducible expression of nearly all class II MHC and related genes is regulated globally at the level of transcription by the class II transactivator (CIITA) (8, 27, 60).”
BackgroundRegulation of major histocompatibility complex class II gene expression in trophoblast cells
Murphy, S. P., Choi, J. C., & Holtz, R. (2004) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-2-52 · Cited by 63
“Transfection of CIITA expression vectors into trophoblast cells, plasma cells, and IFN-γ-inducible cells results in constitutive cell surface expression of MHC class II molecules [11,19-24].”
Sprenkeler, E. G. G., Gresnigt, M. S., & van de Veerdonk, F. L. (2016) · Cellular Microbiology · doi:10.1111/cmi.12616 · Cited by 58
Wang, H.-C. H., & Klein, J. R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6717 · Cited by 60
“However, rapid synthesis of IFN- upon recognition and destruction of Ag-bearing target cells would have a number of beneficial effects, including increases in MHC expression (26), local antiviral activity (27), and enhanced NK cell activity (28).”
BackgroundKakuta, S., Tagawa, Y., Shibata, S., Nanno, M., & Iwakura, Y. (2002) · Immunology · doi:10.1046/j.0019-2805.2001.01342.x · Cited by 62
Matte, C., & Descoteaux, A. (2010) · Infection and Immunity · doi:10.1128/iai.00046-10 · Cited by 64
“This interaction with importin- 5 is central to the nuclear translocation of STAT1 and the subsequent transcriptional regulation of IFN- responsive genes, such as IFN regulatory factor 1 (IRF-1) and class II transactivator (CIITA), which regulate the expression of genes involved in microbial killing and antigen presen…”
BackgroundXu, Y., Wang, L., Butticè, G., Sengupta, P. K., & Smith, B. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404174200 · Cited by 58
Jabrane‐Ferrat, N., Fontes, J. D., Boss, J. M., & Peterlin, B. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4683 · Cited by 58
“In this configuration, RFXs bound to S and X boxes attract the class II transactivator (CIITA), which is required for the subsequent transcriptional activity of class II promoters (5, 38).”
BackgroundThe Bacterial and Viral Agents of BRDC: Immune Evasion and Vaccine Developments
Bell, R. L., Turkington, H. L., & Cosby, S. L. (2021) · Vaccines · doi:10.3390/vaccines9040337 · Cited by 83
“Among its many antiviral functions is the upregulation of crucial signalling peptide MHC II [88,89].”
BackgroundMitochondrial respiration contributes to the interferon gamma response in antigen-presenting cells
Kiritsy, M. C., McCann, K. J., Mott, D., Holland, S. M., Behar, S. M., Sassetti, C. M., & Olive, A. J. (2021) · eLife · doi:10.7554/elife.65109 · Cited by 60
Comparative genetics of the major histocompatibility complex in humans and nonhuman primates
Heijmans, C. M. C., de Groot, N. G., & Bontrop, R. E. (2020) · International Journal of Immunogenetics · doi:10.1111/iji.12490 · Cited by 64
Functional Effects of a Natural Polymorphism in the Transcriptional Regulatory Sequence of HLA-DQB1
Beaty, J. S., West, K. A., & Nepom, G. T. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4771 · Cited by 56
“A protein required for expression of all HLA class II genes is CIITA, which probably functions by interacting with other HLA class II regulatory proteins rather than with DNA directly (40, 41).”
BackgroundZhu, Z., Mao, R., Liu, B., Liu, H., Shi, Z., Zhang, K., Liu, H., Zhang, D., Liu, J., Zhao, Z., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312150121 · Cited by 64
Mach, F. (2002) · Transplant Immunology · doi:10.1016/s0966-3274(02)00030-8 · Cited by 54
Castro, F., Pinto, M. L., Almeida, R., Pereira, F. D. S., da Silva, A. M., Pereira, C. L., Santos, S. G., Barbosa, M. A., Gonçalves, R. M., & Oliveira, M. J. (2019) · Biomaterials Science · doi:10.1039/c9bm00393b · Cited by 60
Itoh-Lindstrom, Y., Piskurich, J. F., Felix, N. J., Wang, Y., Brickey, W. J., Platt, J. L., Koller, B. H., & Ting, J. P. ‐. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.5.2425 · Cited by 67
Sartoris, S., Valle, M. T., Barbaro, A. D. L., Tosi, G., Cestari, T., D’Agostino, A., Megiovanni, A. M., Manca, F., & Accolla, R. S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.814 · Cited by 54
Ghosh, N., Piskurich, J. F., Wright, G. M., Hassani, K., Ting, J. P. ‐., & Wright, K. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32342 · Cited by 55
Nikcevich, K. M., Piskurich, J. F., Hellendall, R. P., Wang, Y., & Ting, J. P. ‐. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00117-4 · Cited by 54
Kohlgruber, A. C., Dezfulian, M. H., Sie, B. M., Wang, C. I., Kula, T., Laserson, U., Larman, H. B., & Elledge, S. J. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02248-6 · Cited by 59
Potentiation by thyroid hormone of human IFN-gamma-induced HLA-DR expression.
Lin, H., Martino, L. J., Wilcox, B. D., Davis, F. B., Gordinier, J., & Davis, P. J. (1998) · PubMed · Cited by 53
Arko‐Mensah, J., Julián, E., Singh, M., & Fernández, C. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01888.x · Cited by 53
Girvin, A. M., Gordon, K. B., Welsh, C. J., Clipstone, N. A., & Miller, S. D. (2002) · Blood · doi:10.1182/blood-2001-12-0229 · Cited by 61
Shukla, A., Cloutier, M., Santharam, M. A., Ramanathan, S., & Ilangumaran, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041964 · Cited by 62
“Another well-characterized NLR protein is NLRA, which does not activate NF-κB or inflammasome, but has been known since the early 90s as the MHC class-II transactivator (CIITA) due to its crucial requirement as a transcriptional coactivator of MHC-II genes [133,134].”
BackgroundSoypeptide lunasin in cytokine immunotherapy for lymphoma
Chang, H., Lewis, D., Tung, C.-Y., Han, L., Henriquez, S. M. P., Voiles, L., Lupov, I. P., Pelloso, D., Sinn, A. L., Pollok, K. E., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1513-8 · Cited by 57
Lee, M. N., & Meyerson, M. M. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf4001 · Cited by 56
“S2D), nonprofessional APCs can support class II expression, either after transduction with CIITA (33) or after expression of defined class II genes (34).”
BackgroundInfluentialBontron, S., Steimle, V., Ucla, C., Eibl, M. M., & Mach, B. (1997) · Human Genetics · doi:10.1007/s004390050403 · Cited by 52
“For instance, cloning of the gene affected in complementation group A, the MHC class II transactivator CIITA (Steimle et al. 1993), has led to the discovery that the product of this gene functions as a general regulator of the expression of MHC class II genes responsible for both constitutive and inducible expression,…”
BackgroundSelf-Association of CIITA and Its Transactivation Potential
Sisk, T. J., Roys, S., & Chang, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.15.4919-4928.2001 · Cited by 52
A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer
Stewart, R. L., Updike, K. L., Factor, R. E., Henry, N. L., Boucher, K. M., Bernard, P. S., & Varley, K. E. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3014 · Cited by 58
“CIITA is the master transcriptional transactivator of the MHCII pathway and is required to induce expression of the other genes in the pathway (48, 49).”
BackgroundImmune evasion as a pathogenic mechanism of varicella zoster virus
Abendroth, A., & Arvin, A. M. (2001) · Seminars in Immunology · doi:10.1006/smim.2001.0293 · Cited by 59
Barry, A., McNulty, M. T., Jia, X., Gupta, Y., Dêbiec, H., Luo, Y., Nagano, C., Horinouchi, T., Jung, S., Colucci, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37985-w · Cited by 59
The IFN‐γ‐induced transcriptional program of the CIITA gene is inhibited by statins
Lee, S. J., Qin, H., & Benveniste, E. N. (2008) · European Journal of Immunology · doi:10.1002/eji.200838189 · Cited by 59
“CIITA is the master regulator of both inducible and constitutive class II MHC expression [28,29].”
BackgroundThompson, J. A., Dissanayake, S. K., Ksander, B. R., Knutson, K. L., Disis, M. L., & Ostrand‐Rosenberg, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2289 · Cited by 50
Taxman, D. J., Cressman, D. E., & Ting, J. P. ‐. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1410 · Cited by 50
Kwak, B. R., Myit, S., Mulhaupt, F., Veillard, N. R., Rufer, N., Roosnek, E. E., & Mach, F. (2002) · Circulation Research · doi:10.1161/hh0302.104924 · Cited by 56
Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis
Keyser, J. D., Laureys, G., Demol, F., Wilczak, N., Mostert, J. P., & Clinckers, R. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.02.012 · Cited by 52
CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression
Downs, I., Vijayan, S., Sidiq, T., & Kobayashi, K. S. (2016) · BioFactors · doi:10.1002/biof.1285 · Cited by 55
Ghasemi, F., Tessier, T. M., Gameiro, S. F., Maciver, A. H., Cecchini, M. J., & Mymryk, J. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-71775-4 · Cited by 58
Expression of MHC Class II-Associated Invariant Chain (Ii;CD74) in Thymic Epithelial Neoplasms
Datta, M. W., Shahsafaei, A., Nadler, L. M., Freeman, G. J., & Dorfman, D. M. (2000) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200009000-00007 · Cited by 49
The class II transactivator CIITA is a transcriptional integrator
Fontes, J. D., Kanazawa, S., Nekrep, N., & Peterlin, B. M. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00232-4 · Cited by 49
MHC Class II Gene Silencing in Trophoblast Cells Is Caused by Inhibition of CIITA Expression
Morris, A. C., Riley, J. L., Fleming, W., & Boss, J. M. (1998) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1998.tb00423.x · Cited by 52
Recent Advances in Mouse Models of Sjögren's Syndrome
Gao, Y., Chen, Y., Zhang, Z., Yu, X., & Zheng, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01158 · Cited by 57
“Regarding the mechanism underlying ectopic expression, IFN-γ produced by salivary gland epithelial cells in RbAp48-tg mice (81) plays an essential role in this process because it can induce high expression of interferon regulatory factor 1 (IRF-1) and class II major histocompatibility complex transactivator (CIITA), w…”
BackgroundMutation in the Class II trans- Activator Leading to a Mild Immunodeficiency
Wiszniewski, W. K., Fondanèche, M., Deist, F. L., Kanariou, M. G., Selz, F., Brousse, N., Steimle, V., Barbieri, G., Alcaïde‐Loridan, C., Charron, D. J., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1787 · Cited by 48
Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
Altomonte, M., Fonsatti, E., Visintin, A., & Maio, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206960 · Cited by 48
“…regulator of MHC class II molecules expression, which not only controls the constitutive expression of MHC class II molecules on professional APC (Steimle et al., 1993, 1994), but also regulates the IFN-g-inducible MHC class II molecules expression on nonprofessional APC (Goodwin et al., 2001).”
BackgroundJu, S., Lee, S., Kwon, T., Heo, S., Park, S., Paek, H., Suh, J., Cho, H. R., Kwon, B., Kwon, B. S., et al. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01330.x · Cited by 51
Interferon γ Repression of Collagen (COL1A2) Transcription Is Mediated by the RFX5 Complex
Xu, Y., Wang, L., Butticè, G., Sengupta, P. K., & Smith, B. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309003200 · Cited by 48
van der Stoep, N., Quinten, E., & van den Elsen, P. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5061 · Cited by 47
Hauber, I., Gulle, H., Wolf, H. M., Maris, M., Eggenbauer, H., & Eibl, M. M. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.4.1411 · Cited by 48
“CIITA is responsible for the class II regulatory defect in the cell lines of the patients and mutants belonging to complementation group II (38, 45).”
BackgroundXi, H., Eason, D. D., Ghosh, D., Dovhey, S. E., Wright, K. L., & Blanck, G. (1999) · Oncogene · doi:10.1038/sj.onc.1202969 · Cited by 49
“Class II transactivator (CIITA) activates the expression of the major histocompatibility class II (MHC class II) genes (Steimle et al., 1993, 1994), which encode cell surface molecules that present antigenic peptides to CD4+ T cells.”
BackgroundThe Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation
Ronzier, E., Laurenson, A. J., Manickam, R., Liu, S., Saintilma, I. M., Schrock, D. C., Hammer, J. A., & Rotty, J. D. (2022) · Cells · doi:10.3390/cells11111806 · Cited by 319
The gamble between oncolytic virus therapy and IFN
Li, Q., Tan, F., Wang, Y., Liu, X., Kong, X., Meng, J., Yang, L., & Cen, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.971674 · Cited by 63
“Apart from the above pathway, type II IFN can trigger the expression of MHCII as well, that is by inducing a different piece of genes through the function of the class II, major histocompatibility complex, transactivator (CIITA) (67).”
BackgroundA backpack-based myeloid cell therapy for multiple sclerosis
Kapate, N., Dunne, M., Kumbhojkar, N., Prakash, S., Wang, L., Graveline, A. R., Park, K. S., Suja, V. C., Goyal, J., Clegg, J. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221535120 · Cited by 51
Missense Variants in HIF1A and LACC1 Contribute to Leprosy Risk in Han Chinese
Wang, D., Fan, Y., Malhi, M., Bi, R., Wu, Y., Xu, M., Yu, X.-F., Long, H., Li, Y., Zhang, D., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.03.006 · Cited by 55
“CIITA is the upstream regulator of HLA genes.(81) Disruption of CIITA might lead to dysregulation of HLA genes, which are main hits for genetic susceptibility to leprosy.”
BackgroundSchnappauf, F., Hake, S. B., Camacho-Carvajal, M. M., Bontron, S., Lisowska‐Grospierre, B., & Steimle, V. (2003) · European Journal of Immunology · doi:10.1002/eji.200323490 · Cited by 58
Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis
Cui, A., Li, B., Wallace, M. S., Gonye, A. L. K., Oetheimer, C., Patel, H., Tonnerre, P., Holmes, J. A., Lieb, D., Yao, B. S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.040 · Cited by 46
“This suggests that neutrophil responses to IFNs are distinct from the known IFN-MHC-II association previously observed in DCs.”
Jagessar, S. A., Holtman, I. R., Hofman, S., Morandi, E., Heijmans, N., Laman, J. D., Gran, B., Faber, B. W., van Kasteren, S. I., Eggen, B. J. L., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600124 · Cited by 47
Maubach, G., Lim, M. C. C., Kumar, S., & Zhuo, L. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.005 · Cited by 46
“[21] and induced the increase in the mRNA levels of the MHC class II molecules and the invariant chain (CD74) as visualized at the later time-points (Fig.”
Background
Metadata
- Authors
- Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., & Mach, B.
- Affiliations
- University of Geneva (CH)
- Jeantet Laboratory of Molecular Genetics, Department of Genetics and Microbiology, University of Geneva Medical School, CH-1211 Geneva 4, Switzerland.
- INSERM U132, Hôpital des Enfants Malades, 15015 Paris, France.
- Venue
- Science
- Published
- 1994-07
- Volume
- 265
- Issue
- 5168
- Pages
- 106-109
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2060320549
- Cited by
- 898
- References
- 29
- Citations by year
- 2026: 33 · 2025: 35 · 2024: 39 · 2023: 49 · 2022: 35 · 2021: 32 · 2020: 25 · 2019: 20 · 2018: 22 · 2017: 19 · 2016: 27 · 2015: 21 · 2014: 18 · 2013: 13 · 2012: 29
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- MHC class II expression, interferon-gamma, CIITA, MHC class II deficiency, gene expression regulation, transcriptional activation
- MeSH terms
- Histocompatibility Antigens Class II, Cell Line, Chromosome Mapping, Chromosomes, Human, Pair 16, Fibroblasts, Gene Expression Regulation, Genes, MHC Class II, Humans, Interferon-gamma, Models, Genetic, Nuclear Proteins, RNA, Messenger, Transfection, Tumor Cells, Cultured, Trans-Activators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.